Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)
Phase 4
Completed
- Conditions
- AtherosclerosisHypercholesterolaemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 153
- Registration Number
- NCT00653835
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)
Phase 4
Completed
- Conditions
- AtherosclerosisHypercholesterolemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 148
- Registration Number
- NCT00653796
Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 280
- Registration Number
- NCT00652717
Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1140
- Registration Number
- NCT00652847
MD Ezetimibe Cyclosporine Interaction (0653-057)
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 13
- Registration Number
- NCT00653276
A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT00652301
Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)
Phase 3
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 167
- Registration Number
- NCT00651560
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
Phase 2
Terminated
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- Drug: etonogestrelDrug: Placebo
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 16
- Registration Number
- NCT00651807
Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
Phase 1
Completed
- Conditions
- HypercholesterolemiaHyperlipidemia
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18
- Registration Number
- NCT00652431
Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)
Phase 4
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 120
- Registration Number
- NCT00652444
© Copyright 2025. All Rights Reserved by MedPath